HIV-1 neutralizing antibodies: How full is the bottle?

被引：76

作者：

Moore, JP ^{[1
]}

Burton, DR

机构：

[1] Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA

[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA

[3] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA

来源：

NATURE MEDICINE | 1999年 / 5卷 / 02期

关键词：

D O I：

10.1038/5502

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Potent neutralizing antibodies protect monkeys from SHIV challenge, but will vaccines ever be able to elicit antibody responses this powerful? (pages 204–216)

引用

页码：142 / 144

页数：3

共 17 条

[1] Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
Belshe, RB
Gorse, GJ
Mulligan, MJ
Evans, TG
Keefer, MC
Excler, JL
Duliege, AM
Tartaglia, J
Cox, WI
McNamara, J
Hwang, KL
Bradney, A
Montefiori, D
Weinhold, KJ
[J]. AIDS, 1998, 12 (18) : 2407 - 2415
[2] Why do we not have an HIV vaccine and how can we make one?
Burton, DR
Moore, JP
[J]. NATURE MEDICINE, 1998, 4 (05) : 495 - 498
[3] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
Connor, RI
Korber, BTM
Graham, BS
Hahn, BH
Ho, DD
Walker, BD
Neumann, AU
Vermund, SH
Mestecky, J
Jackson, S
Fenamore, E
Cao, Y
Gao, F
Kalams, S
Kunstman, KJ
McDonald, D
McWilliams, N
Trkola, A
Moore, JP
Wolinsky, SM
[J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 1552 - 1576
[4] PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY
EMINI, EA
SCHLEIF, WA
NUNBERG, JH
CONLEY, AJ
EDA, Y
TOKIYOSHI, S
PUTNEY, SD
MATSUSHITA, S
COBB, KE
JETT, CM
EICHBERG, JW
MURTHY, KK
[J]. NATURE, 1992, 355 (6362) : 728 - 730
[5] Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
Gauduin, MC
Parren, PWHI
Weir, R
Barbas, CF
Burton, DR
Koup, RA
[J]. NATURE MEDICINE, 1997, 3 (12) : 1389 - 1393
[6] Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
Igarashi, T
Brown, C
Azadegan, A
Haigwood, N
Dimitrov, D
Martin, MA
Shibata, R
[J]. NATURE MEDICINE, 1999, 5 (02) : 211 - 216
[7] Progress in the development of an HIV-1 vaccine
Letvin, NL
[J]. SCIENCE, 1998, 280 (5371) : 1875 - 1880
[8] Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
Montefiori, DC
Pantaleo, G
Fink, LM
Zhou, JT
Zhou, JY
Bilska, M
Miralles, GD
Fauci, AS
[J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) : 60 - 67
[9] Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
Montefiori, DC
Reimann, KA
Wyand, MS
Manson, K
Lewis, MG
Collman, RG
Sodroski, JG
Bolognesi, DP
Letvin, NL
[J]. JOURNAL OF VIROLOGY, 1998, 72 (04) : 3427 - 3431
[10] Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
Polacino, P
Stallard, V
Klaniecki, JE
Montefiori, DC
Langlois, AJ
Richardson, BA
Overbaugh, J
Morton, WR
Benveniste, RE
Hu, SL
[J]. JOURNAL OF VIROLOGY, 1999, 73 (01) : 618 - 630

← 1 2 →